Close Menu

University of Colorado

The ROS1ders advocacy group is 500 patients strong and they are helping researchers establish cell lines to improve understanding of rare ROS1-positve cancers. 

Treatment biomarkers for small cell lung cancer have been nearly non-existent, but researchers are beginning to find ones that mark PARP inhibitor response.